Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03714555 | Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar,… | Phase 2 | terminated | Oct 22, 2018 | HonorHealth Research Institute | Study was closed due to low subject enrollment at site. | Enrollment / accrual |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Phase 2 | terminated | Apr 6, 2018 | Baptist Health South Florida | Slow/poor enrollment | Enrollment / accrual |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and… | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Loss of funding | Funding |
| NCT00769652 | Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer,… | N/A | terminated | Oct 9, 2008 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT03140670 | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not… | Phase 2 | terminated | May 4, 2017 | Abramson Cancer Center at Penn Medicine | Loss of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Phase 1 | terminated | May 27, 2022 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | Phase 2 | terminated | Jun 28, 2022 | Ismail Gögenur | The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included… | Safety / toxicity |
| NCT05043987 | Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With… | Phase 1 | withdrawn | Sep 14, 2021 | Conjupro Biotherapeutics, Inc. | New IND sponsor to initiate a separate study | Other (stated, no rule matched) |
| NCT05379907 | Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer | — | withdrawn | May 18, 2022 | Inova Health Care Services | Determined that the tumor analysis could not be performed in accordance with the protocol. | Other (stated, no rule matched) |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04212026 | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic… | Phase 2 | terminated | Dec 26, 2019 | University Hospital, Basel, Switzerland | difficult recruitement | Enrollment / accrual |
| NCT05216120 | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Phase 2 | withdrawn | Jan 31, 2022 | HonorHealth Research Institute | enrollment challenges | Enrollment / accrual |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT02515513 | The Role of Muscle Cachexia in Pancreatic Cancer | N/A | withdrawn | Aug 4, 2015 | University of Florida | Original PI left the institution. No subjects enrolled | Investigator |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and… | Phase 1 | withdrawn | Jun 24, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT04193904 | A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in… | Phase 1 | terminated | Dec 10, 2019 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Phase 1 / Phase 2 | withdrawn | Feb 22, 2022 | Devalingam Mahalingam | Funder Decision | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking… | Phase 1 | terminated | Apr 18, 2017 | BioNTech Research & Development, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | Phase 1 | withdrawn | Apr 21, 2021 | University of Oxford | Lack of recruitment | Enrollment / accrual |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma…(AntiCEA_CART) | Phase 1 | terminated | Jan 28, 2019 | Sorrento Therapeutics, Inc. | Limited enrollment. | Enrollment / accrual |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic…(ARTEMIS) | — | terminated | May 19, 2022 | Invitae Corporation | Low site engagement and accrual | Enrollment / accrual |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | — | terminated | May 26, 2020 | OHSU Knight Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT04155008 | Nutrition and Pharmacological Algorithm for Oncology Patients Study | Phase 4 | terminated | Nov 7, 2019 | Montefiore Medical Center | The trial was closed after 4 months due to slow to accrual. Only 1 participant was enrolled. | Enrollment / accrual |
| NCT03099265 | Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline… | Phase 2 | terminated | Apr 4, 2017 | Yale University | Paused due to COVID. A determination was made to stop the study because it would be impossible to… | COVID-19 / pandemic |
| NCT02822716 | Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy(IRE) | N/A | terminated | Jul 4, 2016 | Chinese University of Hong Kong | poor case accural | Other (stated, no rule matched) |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | Phase 2 | terminated | Oct 30, 2018 | Northwestern University | The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim… | Efficacy / futility |
| NCT04420130 | A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With… | N/A | withdrawn | Jun 9, 2020 | Yanqiao Zhang | Failed to pass ethics committee review | Other (stated, no rule matched) |
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent… | Phase 1 | withdrawn | Nov 17, 2020 | Ipsen | Business decision not related to any safety or tolerability concern | Safety / toxicity |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT02681601 | Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer | N/A | terminated | Feb 12, 2016 | Jonsson Comprehensive Cancer Center | low accrual | Enrollment / accrual |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | — | withdrawn | Mar 13, 2020 | Beth Israel Deaconess Medical Center | Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected to… | COVID-19 / pandemic |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | N/A | terminated | Jan 6, 2017 | University of Washington | Termination due to slow accrual | Enrollment / accrual |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving… | Early Phase 1 | withdrawn | Jun 10, 2011 | University Hospitals Cleveland Medical Center | Study never started | Other (stated, no rule matched) |
| NCT05212025 | Adavosertib and Gemcitabine in Advanced Pancreatic | Phase 2 | withdrawn | Jan 27, 2022 | James Cleary, MD, PhD | manufacturer choice | Drug supply |
| NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or…(PGPC1) | Phase 2 | terminated | Oct 28, 2011 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT02514031 | ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | Phase 1 | terminated | Aug 3, 2015 | University of Texas Southwestern Medical Center | The study placed on temporarily hold to enrollment due to quality testing necessary for the study… | Enrollment / accrual |
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With… | Phase 1 / Phase 2 | terminated | Mar 31, 2020 | National Cancer Institute (NCI) | Study closed to accrual due to the worsening risk: benefit ratio for participants receiving… | Enrollment / accrual |
| NCT04131192 | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | Phase 1 | terminated | Oct 18, 2019 | Sunshine Lake Pharma Co., Ltd. | Combined with the analysis of the existing data of the trial, there was no obvious advantage… | Other (stated, no rule matched) |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | Phase 2 | withdrawn | Aug 1, 2016 | Wake Forest University Health Sciences | no accrual rate | Enrollment / accrual |
| NCT03165188 | Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L… | — | terminated | May 24, 2017 | NewLink Genetics Corporation | The IND was withdrawn | Other (stated, no rule matched) |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT03300921 | A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic… | Phase 1 | terminated | Oct 4, 2017 | Abramson Cancer Center at Penn Medicine | Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients… | Other (stated, no rule matched) |
| NCT04258150 | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced…(TRIPPLE-R) | Phase 2 | terminated | Feb 6, 2020 | Herlev Hospital | primary endpoint was not met | Other (stated, no rule matched) |
| NCT00447122 | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer | Phase 1 | terminated | Mar 14, 2007 | Brown University | slow enrollment and lack of funding | Enrollment / accrual |
| NCT03784417 | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma | N/A | terminated | Dec 21, 2018 | Catholic University of the Sacred Heart | device unavalaible | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 18, 2023source: clinicaltrials